Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin).
Read morePsychological Flexibility and Psychedelics
In a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.
Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.
Keep reading for the full article at Nature.com
Read morePsychedelics for Soldiers with Trauma
Research suggests that the psychedelic drug MDMA, an empathogenic stimulant also known as Molly or ecstasy, can spark changes in the brain that induce a childlike state of neuroplasticity and help forge new neural connections.
(It could well be approved for PTSD by the U.S. Food and Drugs Administration in August after two advanced stage trials showed significant benefits.)
Researchers are also studying other psychedelics as well, like the powerful drug ibogaine.
Read moreMystical Experiences
Keep reading for an interview with a researcher of mystical experiences.
Read moreThe Science of Death
New research into the dying brain suggests the line between life and death may be less distinct than previously thought.
Read morePsychedelics, Psychosis and Manic Symptoms
In the twin data researchers reviewed, mania was also strongly correlated with a genetic predisposition to schizophrenia and to bipolar I disorder.
In other words, those who experienced manic symptoms after psychedelic use may have been more genetically prone to mental illnesses.
Read moreThe Importance of Therapy!
A study published recently in PLOS One suggests that therapy may, in fact, play an important role in psilocybin-assisted therapy for major depressive disorder.
In a study of 24 participants with MDD, those who reported stronger alliance, or “sense of collaboration between patient and client,” with their therapist were more likely to show improvements in their depression scores after two psilocybin dosing sessions.
Stronger ratings of therapeutic alliance during the study’s final preparation session were correlated with improved depression scores for 12 months after the study.
Read morePsilocybin for Anxiety
Also the trial’s rate of full remission, or a full cessation of symptoms, was five times greater than the placebo group, a marked and compelling difference in treatment outcomes.
Read moreThe Benefits of Psilocybin
Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Click here for the link to this article.
Read moreMDMA, Trauma, Addictions and Psychedelics
Dr. Ben Sessa discusses his latest research here.